U.S. PHARMACOPEIA

Search USP29  
Oxymetazoline Hydrochloride Nasal Solution
» Oxymetazoline Hydrochloride Nasal Solution is a solution of Oxymetazoline Hydrochloride in water adjusted to a suitable tonicity. It contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of C16H24N2O·HCl.
Packaging and storage— Preserve in tight containers.
Identification— Place a volume of Nasal Solution, equivalent to about 2.5 mg of oxymetazoline hydrochloride, in a 60-mL separator, and add water to make about 10 mL. Add 2 mL of sodium carbonate solution (1 in 10), extract with 10 mL of chloroform, and transfer the chloroform extract to a second 60-mL separator. Extract the chloroform solution with 10 mL of 0.1 N hydrochloric acid, allow to separate, and discard the chloroform layer. Transfer 8 mL of the acidic aqueous layer to a test tube, neutralize by the dropwise addition of 1 N sodium hydroxide, add 1 drop of 1 N sodium hydroxide in excess, and mix. Add a few drops of sodium nitroferricyanide TS and 2 drops of sodium hydroxide solution (15 in 100), mix, and allow to stand for 10 minutes. Add 0.1 N hydrochloric acid dropwise until the pH is between 8 and 9, and allow to stand for 10 minutes: a violet color develops.
pH 791: between 4.0 and 6.5.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Assay—
Mobile phase— Prepare as directed in the Assay under Oxymetazoline Hydrochloride.
Standard preparation— Prepare a solution of USP Oxymetazoline Hydrochloride RS in Mobile phase, having a known concentration, approximately equal to the labeled concentration of the Nasal Solution.
Assay preparation— Use Nasal Solution.
Chromatographic system and Procedure—Proceed as directed in the Assay under Oxymetazoline Hydrochloride, except to calculate the quantity, in mg, of C16H24N2O·HCl in each mL of the Nasal Solution taken by the formula:
C(rU / rS),
in which the terms are as defined therein.
Auxiliary Information— Staff Liaison : Feiwen Mao, M.S., Senior Scientific Associate
Expert Committee : (MDOOD05) Monograph Development-Ophthalmics Oncologics and Dermatologicals
USP29–NF24 Page 1612
Phone Number : 1-301-816-8320